VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
SOLV
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
SOLVSolventum Corporation
$76.28$13.2B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

SOLV logoSolventum Corporation(SOLV)Earnings, Financials & Key Ratios

SOLV•NYSE
$76.28
8.6× P/E·Price updated Jul 7, 2026
SectorHealthcareIndustryHealthcare FacilitiesSub-IndustryHealthcare staffing and facility services
AboutSolventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.Show more
  • Revenue$8.32B+0.9%
  • EBITDA$2.67B+67.8%
  • Net Income$1.56B+224.8%
  • EPS (Diluted)8.88+221.7%
  • Gross Margin53.47%-3.9%
  • EBITDA Margin32.07%+66.4%
  • Operating Margin26.2%+108.7%
  • Net Margin18.69%+222.1%
  • ROE38.86%+493.3%

SOLV Price & Volume

Solventum Corporation (SOLV) stock price & volume — 10-year historical chart

Loading chart...

Standalone Operational Transition Strains Profitability Metrics

Investment Thesis • Updated 2026Q1

VerdictNegative
Growth:Contracting
Profitability:Strained
Financial:Strained
Cash Flow:Deteriorating
Primary Risk:Standalone Operational Overhead

Key Thesis Takeaways

  • Solventum faces significant headwinds as it navigates its transition to a standalone entity, characterized by stagnant top-line growth and severe margin compression.
  • The company's reliance on $5.6 billion in goodwill and elevated debt levels creates a precarious financial profile that limits strategic flexibility.
  • Investors should monitor the company's ability to stabilize its operating margins, which have plummeted from 19.9% in 2023Q4 to 4.0% in 2026Q1, before considering a more constructive outlook.

Verdict Logic

the company's inability to sustain positive cash flow, evidenced by a negative 13.6% FCF margin in 2026Q1, combined with persistent revenue stagnation, suggests significant execution risk for the standalone business.

SOLV Growth Metrics

Solventum Corporation (SOLV) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years0.79%
TTM-0.55%

Profit CAGR

10 Years-
5 Years-
3 Years5.03%
TTM277.84%

EPS CAGR

10 Years-
5 Years-
3 Years4.46%
TTM276.5%

Return on Capital

10 Years13.98%
5 Years13.98%
3 Years13.83%
Last Year19.04%

SOLV Recent Earnings

Solventum Corporation (SOLV) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 9/12 qtrs (100%)●Beat Revenue 9/12 qtrs (100%)
Q2 2026Latest
May 5, 2026
Metric
Actual
Est
EPS
$1.48+9.6%
$1.35
Rev
$2.0B+2.0%
$2.0B
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$1.57+4.7%
$1.50
Rev
$2.0B+1.8%
$2.0B
Q4 2025
Nov 6, 2025
Metric
Actual
Est
EPS
$1.50+4.9%
$1.43
Rev
$2.1B+2.0%
$2.1B
Q3 2025
Aug 7, 2025
Metric
Actual
Est
EPS
$1.69+16.6%
$1.45
Rev
$2.2B+2.0%
$2.1B
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 5, 2026
$1.48vs $1.35+9.6%
$2.0Bvs $2.0B+2.0%
Q1 2026Feb 26, 2026
$1.57vs $1.50+4.7%
$2.0Bvs $2.0B+1.8%
Q4 2025Nov 6, 2025
$1.50vs $1.43+4.9%
$2.1Bvs $2.1B+2.0%
Q3 2025Aug 7, 2025
$1.69vs $1.45+16.6%
$2.2Bvs $2.1B+2.0%
Based on last 12 quarters of dataView full earnings history →

Latest SOLV News

Recent stock market news and headlines for Solventum Corporation (SOLV)

Seeking Alpha·Jun 25, 2026
SOLV Energy: The Pullback Makes The Buy Case Stronger

SOLV Energy remains a Buy as the backlog converts into higher-margin earnings, and the stock trades at a compelling valuation discount. MWH's $8.2B backlog and 1.2x book-to-bill offer strong near-term revenue visibility, with O&M and lifecycle services expanding long-term runway. The RWE acquisition strengthens MWH's grid-adjacent capabilities, enabling deeper customer relationships and a greater share of project spend.

Zacks Investment Research·Jun 25, 2026
Why Solventum (SOLV) is a Top Stock for the Long-Term

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

Peers Comparison

Key metrics vs top competitors for Solventum Corporation (SOLV)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SOLV logoSOLVSolventum CorporationCurrent
$76.28$13.21B8.590.86%18.69%38.86%—
BAX logoBAXBaxter International Inc.
$22.86$11.8B-13.065.72%-9.7%-16.5%—
BDX logoBDXBecton, Dickinson and Company
$156.30$56.63B26.818.23%5.33%4.54%—
COO logoCOOThe Cooper Companies, Inc.
$71.89$14.02B38.445.06%5.57%2.84%—
HOLX logoHOLXHologic, Inc.
$76.01$16.97B30.531.74%13.18%11.01%—
ICU logoICUSeaStar Medical Holding Corporation
$5.07$198.66M-0.87814.07%-828.62%-146.29%—

Compare SOLV vs Peers

Solventum Corporation (SOLV) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs BAX

Most directly comparable listed peer for SOLV.

Scale Benchmark

vs TMO

Larger-name benchmark to compare SOLV against a more recognizable public peer.

Peer Set

Compare Top 5

vs BAX, BDX, COO, HOLX

SOLV SEC Filings & Documents

Solventum Corporation (SOLV) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 5, 2026·SEC

Material company update

Mar 24, 2026·SEC

Material company update

Feb 26, 2026·SEC

10-K Annual Reports

2
FY 2026

Feb 27, 2026·SEC

FY 2025

Feb 28, 2025·SEC

10-Q Quarterly Reports

6
FY 2026

May 5, 2026·SEC

FY 2025

Nov 6, 2025·SEC

FY 2025

Aug 8, 2025·SEC

Get notified when SOLV posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SOLV Frequently Asked Questions

Solventum Corporation (SOLV) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Solventum Corporation's revenue?

Solventum Corporation (SOLV) reported $8.26B in revenue for fiscal year 2025. This represents a 1% increase from $8.17B in 2021.

How fast is Solventum Corporation growing?

Solventum Corporation (SOLV) grew revenue by 0.9% over the past year. Growth has been modest.

Is SOLV profitable?

Yes, Solventum Corporation (SOLV) is profitable, generating $1.43B in net income for fiscal year 2025 (18.7% net margin).

Dividend & Returns
What is SOLV's return on equity?

Solventum Corporation (SOLV) has a return on equity (ROE) of 38.9%. This is excellent, indicating efficient use of shareholder capital.

What is Solventum Corporation's free cash flow?

Solventum Corporation (SOLV) had negative free cash flow of $203.0M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in SOLV back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →